NANOG and brain neoplasm: Based on the inability of NANOG-GFP reporter to enrich CSC in cisplatin-resistant cells, we evaluated other CSC enrichment markers including CD49f, which we and others have previously demonstrated to be an informative CSC marker in brain tumors and breast cancer [26–28].